LBA2 | ZANUBRUTINIB PLUS LENALIDOMIDE AND RITUXIMAB VERSUS R‐miniCHOP IN UNFIT OR FRAIL PATIENTS WITH NEWLY DIAGNOSED DIFFUSE LARGE B‐CELL LYMPHOMA AGED 70 YEARS OR OLDER

Peng Xu(Directorate for Cultural Heritage), Zhenwei Shi(Guangdong Academy of Medical Sciences), Hui Lü(Shanghai Jiao Tong University), Zhiming Li(Anhui Medical University), Xiaoning Lu(Nantong University), Guangying Cui(First Affiliated Hospital of Zhengzhou University), Chuan Wang(Fujian Medical University), Jingsong He(York University), Shih‐Chi Chen(Chinese University of Hong Kong), Zhipeng Zhu(Henan Provincial People's Hospital), Jiamin Xu(Shenyang Pharmaceutical University), J. Zhang, S. Cheng(Shenzhen Bioeasy Biotechnology (China)), Alex Z. Fu, Ou Bai, Guifang Ouyang, Xin Wang(Shandong Provincial Hospital), Xin Wang(Xi'an University of Architecture and Technology), Hong Li(Henan Agricultural University), Jing Wang(Anhui Medical University), Rong Li(North Sichuan Medical University), Jing Chen(Chinese Academy of Sciences), Meng Sun(Nanjing University of Chinese Medicine), Fei Li(Xiamen Medical College), He Huang(Peking University), Wei Zhao(Chongqing Emergency Medical Center), Xu Yan(Peking University), Dongxu Zhao(Chinese Academy of Sciences), Yan Xie(Peking University), Li Wang(University of Science and Technology of China), Hon‐Man Liu(National Yang Ming Chiao Tung University), Hui Zhou(Hunan Cancer Hospital)
Hematological Oncology
June 1, 2025
Cited by 2


Related Papers